SEC Form 4 · accession 0001615774-18-004580
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Pappajohn
Director
Period of report
May 25, 2018
Accepted (ET)
May 30, 2018 · 8:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 25, 2018 | A | 4,500 | $2.27 | A | 567,790 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On May 25, 2018, the Board of Directors (the "Board") of MYnd Analytics, Inc. granted the indicated number of restricted shares (the "Shares") in lieu of the remaining amount of the Reporting Person's Board fee for the 2017-2018 fiscal year. The Shares were issued pursuant to the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan.